Vaxcyte, Inc.
NASDAQ:PCVX
Overview | Financials
Company Name | Vaxcyte, Inc. |
Symbol | PCVX |
Currency | USD |
Price | 86.515 |
Market Cap | 10,782,970,055 |
Dividend Yield | 0% |
52-week-range | 58.1 - 121.055 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. Grant E. Pickering M.B.A. |
Website | https://vaxcyte.com |
An error occurred while fetching data.
About Vaxcyte, Inc.
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD